Worth Watching Stocks: Masco Corporation (NYSE:MAS), Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)


Masco Corporation (NYSE:MAS)

Masco Corporation (NYSE:MAS) represented a move of -1.46 percent or $0.3 per share and closed its previous day trading session at $31.03. 4.12 Million Shares were traded in the last trading session with an Average Volume of 3.84 Million Shares. The stock currently has a Market Capitalization of 9.5 Billion.

Masco Corporation is a global leader in the design, manufacture and distribution of branded home improvement and building products. Masco’s portfolio of industry-leading brands includes Behr paint; Delta and Hansgrohe faucets, bath and shower fixtures; KraftMaid and Merillat cabinets; Milgard windows and doors; and Hot Spring spas. The Company leverage their powerful brands across product categories, sales channels and geographies to create value for the customers and shareholders. From Shanghai to Mexico City, to the tallest man-made structure ever built, the Burj Khalifa in Dubai, and throughout the Americas, their products are found around the globe. In hotels, residential homes, public buildings, skyscrapers and commercial buildings of every size, Masco’s products are trusted to deliver innovation, quality design and reliable performance.

The stock traded between $27.15 and $46.44 over 1-Year time period showing its price to sales ratio of 1.16. Masco Corporation (NYSE:MAS) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $-10.65 and 200-Day Simple Moving Average of $-19.23. Its Price to Free Cash Flow is 16.19 and Price to Book of 258.58.

Analyst’s recommended the stock as 2.1 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Masco Corporation (NYSE:MAS) reported its Actual EPS of $0.65/share. The analysts offering Earnings Estimates for the company were believing that Masco Corporation could bring EPS of $0.7/share. The difference between Actual EPS and Estimated EPS was -0.05 Percent. Thus showing an Earnings Surprise of -7.1 Percent.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

In the last trading session, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) added its value by -2.22% closing at the price of $3.08. The stock currently has market capitalization of 310.99 Million, with average volume of 810.54 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is showing beta of 2.05. This particular value of beta suggests that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has historically moved 205% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is at $-0.22.

The stock currently has RSI of 43.98. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven’s patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven’s vigabatrin-related foreign patents or patents pending worldwide. The Company’s initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted Fast Track status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) topped its 52-week high price of $4.51 on 12/01/17 and 52-Week Low Price of $2.18 on 04/04/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 6.14% and monthly volatility of 6.72% respectively.